Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice

References

• Lawrence S. Pipelines turn to biotech. Nat Biotechnol 2007; 25:1342; http://dx.doi.org/10.1038/nbt1207-1342; PMID: 18066015
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305:1460 - 8; http://dx.doi.org/10.1001/jama.2011.406; PMID: 21486979
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66:921 - 6; http://dx.doi.org/10.1136/ard.2006.065615; PMID: 17301106
   PubMed Web of Science ®Google Scholar
• Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1:457 - 62; http://dx.doi.org/10.1038/nrd818; PMID: 12119747
   PubMed Web of Science ®Google Scholar
• Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J 2006; 8:E501 - 7; http://dx.doi.org/10.1208/aapsj080359; PMID: 17025268
   PubMed Web of Science ®Google Scholar
• Braun A, Kwee L, Labow MA, Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 1997; 14:1472 - 8; http://dx.doi.org/10.1023/A:1012193326789; PMID: 9358564
   PubMed Web of Science ®Google Scholar
• Gamble CN. The role of soluble aggregates in the primary immune response of mice to human gamma globulin. Int Arch Allergy Appl Immunol 1966; 30:446 - 55; http://dx.doi.org/10.1159/000229829; PMID: 4163860
   PubMedGoogle Scholar
• Cheng PC, Steele CR, Gu L, Song W, Pierce SK. MHC class II antigen processing in B cells: accelerated intracellular targeting of antigens. J Immunol 1999; 162:7171 - 80; PMID: 10358163
   PubMed Web of Science ®Google Scholar
• Daha MR, van ES LA, Hazevoet HM, Kijlstra A. Degradation of soluble immunoglobulin aggregates in vitro by monocytes from normal subjects and from patients with systemic lupus erythematosus. Scand J Immunol 1982; 16:117 - 22; http://dx.doi.org/10.1111/j.1365-3083.1982.tb00705.x; PMID: 7134889
   PubMed Web of Science ®Google Scholar
• Johnson R, Jiskoot W. Models for evaluation of relative immunogenic potential of protein particles in biopharmaceutical protein formulations. J Pharm Sci 2012; 101:3586 - 92; http://dx.doi.org/10.1002/jps.23248; PMID: 22736238
   PubMed Web of Science ®Google Scholar
• Filipe V, Hawe A, Schellekens H, Jiskoot W. Aggregation and immunogenicity of therapeutic proteins. In: Wang W, Roberts CJ, eds. Aggregation of therapeutic proteins. New Jersey: John Wiley & Sons, 2010:403-33.
   Google Scholar
• Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci 2009; 98:2909 - 34; http://dx.doi.org/10.1002/jps.21566; PMID: 18823031
   PubMed Web of Science ®Google Scholar
• den Engelsman J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, et al. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res 2011; 28:920 - 33; http://dx.doi.org/10.1007/s11095-010-0297-1; PMID: 20972611
   PubMed Web of Science ®Google Scholar
• Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci 2009; 98:1201 - 5; http://dx.doi.org/10.1002/jps.21530; PMID: 18704929
   PubMed Web of Science ®Google Scholar
• Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci 2010; 99:3302 - 21; http://dx.doi.org/10.1002/jps.22097; PMID: 20310025
   PubMed Web of Science ®Google Scholar
• Hawe A, Hulse WL, Jiskoot W, Forbes RT. Taylor dispersion analysis compared to dynamic light scattering for the size analysis of therapeutic peptides and proteins and their aggregates. Pharm Res 2011; 28:2302 - 10; http://dx.doi.org/10.1007/s11095-011-0460-3; PMID: 21560019
   PubMed Web of Science ®Google Scholar
• Filipe V, Hawe A, Jiskoot W. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 2010; 27:796 - 810; http://dx.doi.org/10.1007/s11095-010-0073-2; PMID: 20204471
   PubMed Web of Science ®Google Scholar
• Barnard JG, Singh S, Randolph TW, Carpenter JF. Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway. J Pharm Sci 2011; 100:492 - 503; http://dx.doi.org/10.1002/jps.22305; PMID: 20803602
   PubMed Web of Science ®Google Scholar
• Wuchner K, Büchler J, Spycher R, Dalmonte P, Volkin DB. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation. J Pharm Sci 2010; 99:3343 - 61; http://dx.doi.org/10.1002/jps.22123; PMID: 20229596
   PubMed Web of Science ®Google Scholar
• Barnard JG, Rhyner MN, Carpenter JF. Critical evaluation and guidance for using the Coulter method for counting subvisible particles in protein solutions. J Pharm Sci 2012; 101:140 - 53; http://dx.doi.org/10.1002/jps.22732; PMID: 22109687
   PubMed Web of Science ®Google Scholar
• De Groot AS, McMurry J, Moise L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 2008; 8:620 - 6; http://dx.doi.org/10.1016/j.coph.2008.08.002; PMID: 18775515
   PubMed Web of Science ®Google Scholar
• Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, et al. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin Immunol 2010; 137:5 - 14; http://dx.doi.org/10.1016/j.clim.2010.06.018; PMID: 20708973
   PubMed Web of Science ®Google Scholar
• Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, et al. Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses. J Biol Chem 2012; 287:25266 - 79; http://dx.doi.org/10.1074/jbc.M111.330902; PMID: 22584577
   PubMed Web of Science ®Google Scholar
• Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci 2006; 95:1084 - 96; http://dx.doi.org/10.1002/jps.20599; PMID: 16552750
   PubMed Web of Science ®Google Scholar
• van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm Res 2010; 27:1812 - 24; http://dx.doi.org/10.1007/s11095-010-0172-0; PMID: 20499141
   PubMed Web of Science ®Google Scholar
• Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res 2011; 28:2379 - 85; http://dx.doi.org/10.1007/s11095-011-0523-5; PMID: 21744171
   PubMed Web of Science ®Google Scholar
• Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 2008; 14:191 - 202; http://dx.doi.org/10.1016/S1387-2656(08)00007-0; PMID: 18606364
   PubMedGoogle Scholar
• van Beers MM, Sauerborn M, Gilli F, Hermeling S, Brinks V, Schellekens H, et al. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta. J Immunol Methods 2010; 352:32 - 7; http://dx.doi.org/10.1016/j.jim.2009.10.005; PMID: 19857496
   PubMed Web of Science ®Google Scholar
• Hermeling S, Jiskoot W, Crommelin D, Bornaes C, Schellekens H. Development of a transgenic mouse model immune tolerant for human interferon Beta. Pharm Res 2005; 22:847 - 51; http://dx.doi.org/10.1007/s11095-005-4578-z; PMID: 15948027
   PubMed Web of Science ®Google Scholar
• Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci 2006; 95:1084 - 96; http://dx.doi.org/10.1002/jps.20599; PMID: 16552750
   PubMed Web of Science ®Google Scholar
• Nicholson IC, Zou X, Popov AV, Cook GP, Corps EM, Humphries S, et al. Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes. J Immunol 1999; 163:6898 - 906; PMID: 10586092
   PubMed Web of Science ®Google Scholar
• Kelly SM, Jess TJ, Price NC. How to study proteins by circular dichroism. Biochim Biophys Acta 2005; 1751:119 - 39; http://dx.doi.org/10.1016/j.bbapap.2005.06.005; PMID: 16027053
   PubMed Web of Science ®Google Scholar
• Hawe A, Sutter M, Jiskoot W. Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res 2008; 25:1487 - 99; http://dx.doi.org/10.1007/s11095-007-9516-9; PMID: 18172579
   PubMed Web of Science ®Google Scholar
• Demeule B, Lawrence MJ, Drake AF, Gurny R, Arvinte T. Characterization of protein aggregation: the case of a therapeutic immunoglobulin. Biochim Biophys Acta 2007; 1774:146 - 53; http://dx.doi.org/10.1016/j.bbapap.2006.10.010; PMID: 17142116
   PubMed Web of Science ®Google Scholar
• Pelton JT, McLean LR. Spectroscopic methods for analysis of protein secondary structure. Anal Biochem 2000; 277:167 - 76; http://dx.doi.org/10.1006/abio.1999.4320; PMID: 10625503
   PubMed Web of Science ®Google Scholar
• Imanishi A, Isemura T. Circular dichroic spectra of L-cystine and its dihydrochloride crystals in KBr disc in relation to the circular dichroism of disulfide bonds in proteins. J Biochem 1969; 65:309 - 12; PMID: 5771957
   PubMed Web of Science ®Google Scholar
• Hermeling S, Aranha L, Damen JM, Slijper M, Schellekens H, Crommelin DJ, et al. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 2005; 22:1997 - 2006; http://dx.doi.org/10.1007/s11095-005-8177-9; PMID: 16184451
   PubMed Web of Science ®Google Scholar
• Schellekens H.. Immunogenicity of therapeutic proteins. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association. European Renal Association 2003; 18:1257 - 9
   Google Scholar
• Ottesen JL, Nilsson P, Jami J, Weilguny D, Dührkop M, Bucchini D, et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 1994; 37:1178 - 85; http://dx.doi.org/10.1007/BF00399790; PMID: 7895946
   PubMed Web of Science ®Google Scholar
• Weksler ME, Bull G, Schwartz GH, Stenzel KH, Rubin AL. Immunologic responses of graft recipients to antilymphocyte globulin: effect of prior treatment with aggregate-free gamma globulin. J Clin Invest 1970; 49:1589 - 95; http://dx.doi.org/10.1172/JCI106376; PMID: 4194090
   PubMed Web of Science ®Google Scholar
• Cerottini JC, Lambert PH, Dixon FJ. Comparison of the immune responsiveness of NZB and NZB X NZW F1 hybrid mice with that of other strains of mice. J Exp Med 1969; 130:1093 - 105; http://dx.doi.org/10.1084/jem.130.5.1093; PMID: 4186796
   PubMed Web of Science ®Google Scholar
• Biro CE, Garcia G. The Antigenicity of Aggregated and Aggregate-Free Human Gamma-Globulin for Rabbits. Immunology 1965; 8:411 - 9; PMID: 14279046
   PubMed Web of Science ®Google Scholar
• Golub ES, Weigle WO. Studies on the induction of immunologic unresponsiveness. 3. Antigen form and mouse strain variation. J Immunol 1969; 102:389 - 96; PMID: 4179469
   PubMed Web of Science ®Google Scholar
• Fujiwara M, Fujiwara S, Yoshizaki C, Awaya A. Strain differences in the immunogenicity of aggregated human IgG and the adjuvant action of lipopolysaccharide on the low-responder strain of mice. Jpn J Microbiol 1976; 20:141 - 6; PMID: 781351
   PubMedGoogle Scholar
• Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 1980; 51:691 - 7; http://dx.doi.org/10.1210/jcem-51-4-691; PMID: 7419661
   PubMed Web of Science ®Google Scholar
• van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm Res 2011; 28:2393 - 402; http://dx.doi.org/10.1007/s11095-011-0451-4; PMID: 21544687
   PubMed Web of Science ®Google Scholar
• Philo JS. Is any measurement method optimal for all aggregate sizes and types?. AAPS J 2006; 8:E564 - 71; http://dx.doi.org/10.1208/aapsj080365; PMID: 17025274
   PubMed Web of Science ®Google Scholar
• Stadtman ER. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radic Biol Med 1990; 9:315 - 25; http://dx.doi.org/10.1016/0891-5849(90)90006-5; PMID: 2283087
   PubMed Web of Science ®Google Scholar
• Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001; 13:114 - 9; http://dx.doi.org/10.1016/S0952-7915(00)00191-6; PMID: 11154927
   PubMed Web of Science ®Google Scholar
• Li S, Nguyen TH, Schöneich C, Borchardt RT. Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. Biochemistry 1995; 34:5762 - 72; http://dx.doi.org/10.1021/bi00017a008; PMID: 7727437
   PubMed Web of Science ®Google Scholar
• Zimm BH. The dependence of the scattering of light on angle and concentration in linear polymer solutions. J Phys Colloid Chem 1948; 52:260 - 7; http://dx.doi.org/10.1021/j150457a022; PMID: 18918874
   PubMedGoogle Scholar
• Aghaie A, Pourfathollah AA, Bathaie SZ, Moazzeni SM, Pour HK, Banazadeh S. Structural study on immunoglobulin G solution after pasteurization with and without stabilizer. Transfus Med 2008; 18:62 - 70; http://dx.doi.org/10.1111/j.1365-3148.2007.00778.x; PMID: 18279194
   PubMed Web of Science ®Google Scholar
• van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010; 362:82 - 8; http://dx.doi.org/10.1016/j.jim.2010.09.005; PMID: 20833178
   PubMed Web of Science ®Google Scholar